Raymond James & Associates Provention Bio, Inc. Transaction History

Raymond James & Associates

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	SELL	$6.7 - $24.21 $36,555 - $132,089	-5,456 Reduced 24.71%	16,626 $400,000
Q4 2022 Feb 08, 2023	BUY	$4.52 - $10.57 $16,271 - $38,052	3,600 Added 19.48%	22,082 $233,000
Q3 2022 Oct 25, 2022	BUY	$3.43 - $5.62 $19,386 - $31,764	5,652 Added 44.05%	18,482 $83,000
Q2 2022 Aug 12, 2022	BUY	$3.65 - $7.3 $5,219 - $10,439	1,430 Added 12.54%	12,830 $51,000
Q1 2022 May 11, 2022	SELL	$3.4 - $7.88 $29,240 - $67,768	-8,600 Reduced 43.0%	11,400 $83,000
Q4 2021 Feb 08, 2022	BUY	$5.59 - $7.39 $139 - $184	25 Added 0.13%	20,000 $112,000
Q3 2021 Nov 02, 2021	BUY	$5.66 - $8.33 $14,433 - $21,241	2,550 Added 14.63%	19,975 $128,000
Q2 2021 Aug 11, 2021	BUY	$6.71 - $11.04 $5,260 - $8,655	784 Added 4.71%	17,425 $147,000
Q1 2021 May 14, 2021	BUY	$10.12 - $19.45 $13,358 - $25,674	1,320 Added 8.62%	16,641 $175,000
Q4 2020 Feb 12, 2021	SELL	$11.79 - $18.94 $742 - $1,193	-63 Reduced 0.41%	15,321 $260,000
Q3 2020 Nov 04, 2020	BUY	$10.34 - $15.2 $55,008 - $80,864	5,320 Added 52.86%	15,384 $197,000
Q2 2020 Jul 28, 2020	BUY	$7.81 - $17.0 $78,599 - $171,088	10,064 New	10,064 $142,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.